Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

European Journal of Cancer

Volumn 40, Issue 11, 2004, Pages 1704-1712

  Diel, I J ^a   Body, J J ^b   Lichinitser, M R ^c   Kreuser, E D ^d   Dornoff, W ^e   Gorbunova, V A ^c   Budde, M ^f   Bergstrom B ^g  

^a CGG Klinik GmbH   (Germany)

^b JULES BORDET INSTITUTE   (Belgium)

^c Cancer Research Center   (Russian Federation)

^d Hospital Barmherzigen Brueder   (Germany)

^e Klinik Mutterhaus der Borromaeerinnen   (Germany)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g HOFFMANN LA ROCHE INC   (United States)

Author keywords

Bisphosphonate; Bone pain; Breast cancer; Ibandronate; Intravenous; Metastatic bone disease; Quality of life

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CODEINE; DEXTROPROPOXYPHENE; IBANDRONIC ACID; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; TRAMADOL;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; EMOTION; FATIGUE; FEMALE; FLU LIKE SYNDROME; FRACTURE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; SCORING SYSTEM; SOCIAL STATUS;

EID: 3142648920     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.03.025     Document Type: Article

References (24)

1. Scheid V., Buzdar A.U., Smith T.L., et al. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 58:1986;2589-2593
2. Theriault R.L., Hortobagyi G.N. Bone metastasis in breast cancer. Anticancer Drugs. 3:1992;455-462
3. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br. J. Cancer. 55:1987;61-66
4. Coleman R.E., Smith P., Rubens R.D. Clinical course and prognostic factors following bone recurrence from breast cancer. Br. J. Cancer. 77:1998;336-340
5. Solomayer E.F., Diel I.J., Meyberg G.C., et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res. Treat. 59:2000;271-278
6. Hillner B.E., Ingle J.N., Berensen J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J. Clin. Oncol. 18:2000;1378-1391
7. Rodan G.A., Fleisch H.A. Bisphosphonates: mechanisms of action. J. Clin. Invest. 97:1996;2692-2696
8. Rogers M.J., Frith J.C., Luckman S.P., et al. Molecular mechanism of action of bisphosphonates. Bone. 24(Suppl. 1):1999;S73-S79
9. Paterson A.H.G., Powles T.J., Kanis J.A., et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:1993;59-65
10. Van Holten-Verzantvoort A.T.M., Kroon H.M., Bijvoet O.L.M., et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:1993;491-498
11. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335:1996;1785-1791
12. Thériault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J. Clin. Oncol. 17:1999;846-854
13. Kristensen B., Ejlertsen B., Groenvold M., et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med. 246:1999;67-74
14. Mühlbauer R.C., Bauss F., Schenk R., et al. Ibandronate, a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 9:1991;1003-1011
15. Pecherstorfer M., Herrmann Z., Body J.J., et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J. Clin. Oncol. 14:1996;268-276
16. Ralston S.H., Thiébaud D., Herrmann Z., et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br. J. Cancer. 75:1997;295-300
17. Pecherstorfer M., Ludwig H., Schlosser K., Buck S., Huss H.J., Body J.J. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J. Bone Miner. Res. 11:1996;587-593
18. Body J.-J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14:2003;1399-1405
19. Van Holten-Verzantvoort A.T., Zwinderman A.H., Aaronson N.K., et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur. J. Cancer. 27:1991;544-549
20. Coleman R.E. Assessment of response to treatment. Rubens R.D., Fogelman I. Bone metastases: diagnosis and treatment. 1991;99-120 Springer, New York
21. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J. Nat. Cancer. Inst. 85:1993;365-375
22. O'Brien P.C. Procedures for comparing samples with multiple endpoints. Biometrics. 40:1984;1079-1087
23. Osoba D., Tannock F., Ernst D.S., Neville A.J. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J. Clin. Oncol. 17:1999;1654-1663
24. Goodwin P.J., Black J.T., Bordeleau L.J., Ganz P.A. Health-related quality-of-life measurement in randomized clinical trials in breast cancer - taking stock. J. Nat. Cancer Inst. 95:2003;263-281